News

Zogenix Opens Photo Contest to Benefit Advocacy Groups

The biopharmaceutical company Zogenix is introducing a Dravet syndrome community photo-sharing campaign and contest to benefit the Dravet Syndrome Foundation and the Epilepsy Foundation. U.S. families of Dravet patients whose seizures are treated with Fintepla (fenfluramine) — an add-on therapy developed by Zogenix — may enter the…

Takeda Closes Deal With Ovid for Soticlestat

Ovid Therapeutics has closed an agreement under which Takeda Pharmaceuticals will secure global rights to develop and market the investigational oral therapy soticlestat (previously TAK-935/OV935) for two rare epilepsy syndromes, one of which is Dravet syndrome, the company announced. Takeda had announced the exclusive agreement…